Conversation Series | ED Discussions in Primary Care | Dr Tom Silva
The second video from our Conversation Series with Dr Thomas Silva is now live. Dr Silva is a specialist GP and University of Queensland lecturer who brings unique expertise in erectile dysfunction treatment, including experience with complex post-prostate cancer cases. In this conversation, Dr Silva shares his clinical experience with SPONTAN®, discussing how the innovative […]
The Medical Republic | Erectile Dysfunction Telehealth Platform to Launch
LTR Pharma’s exciting new joint venture with Restorative Sexual Health Clinic (RSHC) to launch an online healthcare platform dedicated to men’s health has been featured in The Medical Republic. Here’s an excerpt: ‘𝘔𝘦𝘭𝘪𝘴𝘴𝘢 𝘏𝘢𝘥𝘭𝘦𝘺 𝘉𝘢𝘳𝘳𝘦𝘵𝘵, 𝘧𝘰𝘶𝘯𝘥𝘦𝘳 𝘰𝘧 𝘵𝘩𝘦 𝘙𝘚𝘏𝘊 𝘴𝘢𝘪𝘥: “𝘛𝘩𝘪𝘴 𝘱𝘢𝘳𝘵𝘯𝘦𝘳𝘴𝘩𝘪𝘱 𝘢𝘭𝘪𝘨𝘯𝘴 𝘱𝘦𝘳𝘧𝘦𝘤𝘵𝘭𝘺 𝘸𝘪𝘵𝘩 𝘰𝘶𝘳 𝘮𝘪𝘴𝘴𝘪𝘰𝘯 𝘵𝘰 𝘱𝘳𝘰𝘷𝘪𝘥𝘦 𝘤𝘰𝘮𝘱𝘳𝘦𝘩𝘦𝘯𝘴𝘪𝘷𝘦, 𝘦𝘷𝘪𝘥𝘦𝘯𝘤𝘦-𝘣𝘢𝘴𝘦𝘥 𝘤𝘢𝘳𝘦 𝘵𝘩𝘢𝘵 𝘦𝘯𝘩𝘢𝘯𝘤𝘦𝘴 𝘮𝘦𝘯’𝘴 […]
Joint Venture with Leading Australian Men’s Health Group to Launch Online Platform
LTR Pharma has announced that it has partnered with the Restorative Sexual Health Clinic (RSHC) to establish an innovative online men’s health platform to provide access to healthcare professionals, therapeutic services, and treatments. The joint venture leverages RSHC’s extensive clinical expertise in men’s healthcare and positions LTR Pharma to capitalise on the significant growth in […]
Life Sciences Review | “APAC’s Top Clinical Stage Biopharmaceutical Company”
LTR Pharma has been named “APAC’s Top Clinical Stage Biopharmaceutical Company” and featured in a cover story by global life sciences publication, Life Sciences Review . Featuring Executive Chairman Lee Rodne, the article highlights the Company’s vision of enhancing men’s health and wellbeing by reimagining the treatment landscape for men with Erectile Dysfunction (ED) with […]
Conversation Series | Meet the Expert | Dr Tom Silva
Welcome to LTR Pharma’s latest Conversation Series with Dr Tom Silva – a respected key opinion leader (KOL) in men’s health. Dr Silva is specialist GP and University of Queensland lecturer who brings unique expertise in erectile dysfunction treatment, including experience with complex post-prostate cancer cases. In this conversation, Dr Silva shares clinical perspectives on […]
AUSBIZ | Interview with Lee Rodne
This week, LTR Pharma announced the key findings of its pivotal clinical study of SpontanÒ, demonstrating that the nasal spray is absorbed 470% faster than oral tablets. Executive Chairman, Lee Rodne, recently spoke with @ausbiz anchor Nadine Blayney about the significance of these findings, the Company’s plans to target the US market, and the importance […]
Biotech Dispatch | LTR Pharma says Spontan achieves faster absorption in completed pivotal study
LTR Pharma’s announcement of key results from its pivotal study of SPONTAN has been shared in industry publication, Biotech Daily. Click to read the article.
Stockhead | LTR Pharma’s pivotal trial shows SPONTAN outperforms oral ED tablets
LTR Pharma has been featured in a Special Report in Stockhead, following the announcement of data from the Company’s pivotal study demonstrating that SPONTAN nasal spray is absorbed 470% faster absorption than oral vardenafil. Click here to read the report.
Professor Chung elected President of International Society of Sexual Medicine (ISSM)
Congratulations to LTR Pharma’s Scientific and Clinical Advisor, Professor Eric Chung, on his appointment as President-elect of the International Society of Sexual Medicine (ISSM). The ISSM is a leading international organisation dedicated to advancing the field of sexual medicine. As a trusted source of information, education, and professional development, the ISSM ensures that the latest […]
Conversation Series | Myth Busting about Erectile Dysfunction
This week, Professor Chung shares insights on the common misconceptions about the lived experience of Erectile Dysfunction (ED); myths in relation to treatment of ED, his professional views on the particular issues around the context of men’s sexual health and why he believes SPONTAN® is being welcomed as a potential solution for ED. At LTR […]
Money | The new Viagra alternative you can invest in
Online magazine Money has published an article by Stuart Bromley highlighting the investment opportunity with LTR Pharma, as it progresses the development of SPONTAN nasal spray for the treatment of Erectile Dysfunction (ED). Here’s excerpt: “While most current treatments are off patent and generic, making them quite cheap, it is believed that many consumers looking […]
LTP Secures Global Co-Development Agreement with Aptar Pharma
LTR Pharma has today announced it has entered into a Comprehensive Co-Development Agreement with Aptar Pharma for SPONTAN® for global markets. APTAR is a global leader in the design and manufacturing of a broad range of drug and consumer product dosing, dispensing and protection technologies. APTAR has substantial FDA regulatory expertise and its delivery systems […]
The West Australian | A Treatment on the Up
LTR Pharma has been featured in The West Australian, in an article titled ‘A Treatment on the Up’ by business journalist Cheyanne Enciso highlighting the significance of Australian patients being the first in the world to access to a PDE5 nasal-spray treatment for erectile dysfunction, SPONTAN®. The article includes comments from Melissa Hadley Barrett, founder […]
SYNTHETIC | Interview with Lee Rodne
LTR Pharma Executive Chairman, Lee Rodne, recently spoke with Simons Chase of Synthetic.com, taking a deep dive into the Company’s future plans to bring SPONTAN, its “first-in-class” rapid onset, on-demand therapeutic nasal spray for the treatment of erectile dysfunction (ED), to the Australian and US markets. Take a look:
SPONTAN® prescribed to first patient under TGA Special Access Scheme
LTR Pharma has today announced that SPONTAN® has been prescribed to the first patients under the TGA’s Special Access Scheme (SAS). Patients were prescribed by the Restorative Sexual Health Clinic (RSHC), which provides evidence-based care to help individuals achieve optimal sexual function and improve intimate relationships. Restorative Sexual Health Clinic’s founder, Melissa Hadley Barrett, said, […]
Ausbiz | Interview with Lee Rodne
Following this week’s announcement of a successful $10.5M capital raise, LTR Pharma’s Executive Chairman, Lee Rodne, spoke with ausbiz about future plans for the commercial launch of fast-acting nasal spray treatment for erectile dysfunction, SPONTAN. Watch the video.
Stockhead Shortz | Interview with Lee Rodne
In an interview with Stockhead‘s Sarah Hughan, LTR Pharma Executive Chairman Lee Rodne spoke of the Company’s successful $10.5 million capital raise, and how the funds would be allocated to fast-track commercialisation of its fast-acting nasal spray treatment for erectile dysfunction (ED), SPONTAN. “We’re scaling up our commercial manufacturing, and getting prepared to launch here […]
The Australian Business Review | LTP Pharma raises $10.5m to advance erectile dysfunction treatment SPONTAN
LTR Pharma’s A$10.5 million share placement has been featured in The Australian Business Review. Click to read the article.
LTR Pharma completes A$10.5 million placement to expedite commercialisation of SPONTAN®
LTR Pharma has today announced that it has successfully completed a A$10.5 million Share Placement to sophisticated and new institutional investors to expedite the commercialisation of SPONTAN®. Funds will be deployed to advance SPONTAN’s regulatory pathways, expand R&D pipeline, and bolster sales and marketing efforts. LTR Pharma Chairman, Lee Rodne, commented: “This capital injection will […]
Conversation Series | Treatment Innovation for ED – Introduction to SPONTAN®
The fourth instalment of the LTR Pharma Conversation Series is now live. This week, Professor Chung shares insights into nasal delivery technology and why it is an effective pathway to treat erectile dysfunction; clinical evidence to support the benefits and mechanism of action of SPONTAN®; and why patients are interested in this new treatment. For […]